Genethera Inc (GTHR) financial statements (2022 and earlier)

Company profile

Business Address 3051 W 105TH AVENUE
WESTMINSTER, CO 80031
State of Incorp. NV
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
ASSETS
Current Assets
Prepaid expense1111121 
Total current assets:1111121 
Noncurrent Assets
Property, plant and equipment78911121315
Total noncurrent assets:78911121315
TOTAL ASSETS:891012241415
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,2547,1367,0176,8806,7536,4626,261
Accounts payable81818181812928
Accrued liabilities7,1737,0556,9366,7996,6726,4336,233
Debt26262626262626
Due to related parties721730744732710735738
Other undisclosed current liabilities  5555555555
Total current liabilities:8,0017,8927,8427,6927,5447,2777,079
Noncurrent Liabilities
Other undisclosed liabilities6455     
Total liabilities:8,0657,9477,8427,6927,5447,2777,079
Stockholders' equity
Stockholders' equity attributable to parent, including:(8,051)(7,938)(7,831)(7,681)(7,519)(7,260)(7,064)
Common stock31292624243636
Additional paid in capital23,83523,70723,53023,47623,47623,44923,449
Accumulated deficit(31,996)(31,753)(31,466)(31,260)(31,099)(30,825)(30,629)
Other undisclosed stockholders' equity attributable to parent80808080808080
Other undisclosed stockholders' equity(6)  (0)0(3) 
Total stockholders' equity:(8,057)(7,938)(7,831)(7,681)(7,519)(7,263)(7,064)
TOTAL LIABILITIES AND EQUITY:891012241415

Income statement (P&L) ($ in thousands)

9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
Operating expenses(242)(285)(205)(132)(273)(194)(142)
Other operating expense, net
(Other Expenses)
(2)      
Other undisclosed operating income2      
Operating loss:(242)(285)(205)(132)(273)(194)(142)
Nonoperating expense(2)      
Interest and debt expense  (2)(29)(2)(2)(2)
Other undisclosed loss from continuing operations before equity method investments, income taxes (2)     
Net loss available to common stockholders, diluted:(244)(286)(206)(161)(274)(196)(143)

Comprehensive Income ($ in thousands)

9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
Net loss:(244)(286)(206)(161)(274)(196)(143)
Comprehensive loss, net of tax, attributable to parent:(244)(286)(206)(161)(274)(196)(143)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: